Algert Global LLC trimmed its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 67.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,554 shares of the company's stock after selling 26,494 shares during the period. Algert Global LLC's holdings in TransMedics Group were worth $783,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Clear Creek Financial Management LLC acquired a new stake in TransMedics Group in the fourth quarter valued at approximately $352,000. Vaughan Nelson Investment Management L.P. grew its holdings in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after purchasing an additional 32,605 shares during the period. Baillie Gifford & Co. grew its holdings in TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock valued at $16,824,000 after purchasing an additional 34,947 shares during the period. State of Michigan Retirement System acquired a new stake in TransMedics Group in the fourth quarter valued at approximately $6,734,000. Finally, Peregrine Capital Management LLC grew its holdings in TransMedics Group by 64.0% in the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock valued at $4,124,000 after purchasing an additional 25,814 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on TMDX shares. Oppenheimer lifted their price target on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Piper Sandler reaffirmed an "overweight" rating and issued a $125.00 price target (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $126.70.
View Our Latest Stock Report on TMDX
Insiders Place Their Bets
In other news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares of the company's stock, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.00% of the stock is owned by company insiders.
TransMedics Group Trading Down 0.5%
Shares of NASDAQ TMDX traded down $0.61 during trading on Friday, reaching $121.20. The stock had a trading volume of 413,421 shares, compared to its average volume of 1,353,563. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business's 50-day moving average price is $82.91 and its 200-day moving average price is $75.67. The company has a market cap of $4.10 billion, a P/E ratio of 128.91 and a beta of 1.91.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same period in the previous year, the firm posted $0.35 earnings per share. The company's revenue was up 48.2% on a year-over-year basis. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.
About TransMedics Group
(
Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Recommended Stories
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
